Aspirin lowers VTE recurrence: study

Lead author Professor John Simes, director of the NHMRC Clinical Trials Centre at the University of Sydney, said two clinical trials investigated the effect of aspirin on the prevention of recurrent venous thromboembolism in people who had already suffered a pulmonary embolism or deep vein thrombosis – the warfarin and acetylsalicylic acid study (WARFASA) and the Aspirin to Prevent Recurrent Venous Thromboembolism (ASPIRE) trial.

Both showed that aspirin reduces the risk of recurrent VTE but neither was powered to detect the moderate treatment effect for particular subgroups.  

But a re-analysis of the trials, which included data on 1224 patients who had an unprovoked VTE and who had completed initial treatment with heparin and warfarin or an equivalent anticoagulant, found those who received 100mg of enteric-coated aspirin daily for a median of 30.4 months reduced their risk of recurrent VTE by about 40% compared to patients who received placebo.